Spatiotemporal Trends of Hepatitis C in Slovakia: A Joinpoint and GIS-Based Analysis (2015–2025)

Authors

DOI:

https://doi.org/10.32782/2077-6594/2026.2/05

Keywords:

Hepatitis C, Epidemiology, Joinpoint regression, GIS, Marginalised communities, Public health

Abstract

Purpose. The aim of this study was to analyse spatiotemporal trends in hepatitis C incidence in the Banská Bystrica Region and to evaluate the role of community-based screening in the early detection of HCV infection in marginalised populations. Materials and methods. A community-based cross-sectional study was conducted between 2024 and 2025 in selected districts of the Banská Bystrica Region. Participants were recruited through outreach activities targeting marginalised communities. Data were collected using an anonymous questionnaire assessing socio-demographic characteristics and hepatitis-related knowledge. Anti-HCV antibody testing was performed using a rapid diagnostic test. Temporal trends were analysed using Joinpoint regression, and spatial distribution of cases was assessed. Results. A total of 278 individuals were tested during community-based screening activities conducted between 2024 and 2025. In 2024, the prevalence of anti-HCV positivity was 2.0 %, increasing to 16.0 % in 2025. The incidence of chronic hepatitis C in the Banská Bystrica Region increased from 15.7 per 100,000 population in 2024 to 17.8 per 100,000 population in 2025. Joinpoint regression analysis identified a decreasing trend in hepatitis C incidence during 2015–2018 (APC −37.6 %; p < 0.05), followed by a statistically significant increasing trend during 2018–2025 (APC +37.7 %; p < 0.05). Spatial analysis revealed geographical clustering of HCV-positive cases, predominantly in the Lučenec district, followed by Rimavská Sobota. Conclusions. The findings indicate ongoing HCV transmission in marginalised communities and highlight the importance of community-based screening for early detection. Identification of high-risk areas may support targeted micro-elimination strategies and improve access to diagnostics and care.

References

World Health Organization. Global hepatitis report 2024. Geneva: WHO; 2024 [cited 2026 Jan 15]. Available from: https://www.who.int/publications/i/item/9789240091672

Sallam M, Khalil R. Contemporary insights into hepatitis C virus: a comprehensive review. Microorganisms. 2024;12(6):1035. DOI: https://doi.org/10.3390/microorganisms12061035

Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al. Impact of COVID-19 on global hepatitis C elimination efforts. J Hepatol. 2021;74(1):31–36. DOI: https://doi.org/10.1016/j.jhep.2020.08.027

European Centre for Disease Prevention and Control. Monitoring responses to hepatitis B and C epidemics in EU/EEA Member States. Stockholm: ECDC; 2022 [cited 2026 Jan 15]. Available from: https://www.ecdc.europa.eu

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):S45–S57. DOI: https://doi.org/10.1016/j.jhep.2014.07.027

European Centre for Disease Prevention and Control. Hepatitis C – Annual epidemiological report 2023. Stockholm: ECDC; 2023 [cited 2026 Jan 15]. Available from: https://www.ecdc.europa.eu/en/publications-data/hepatitis-c-annual-epidemiological-report-2023

European Centre for Disease Prevention and Control. Hepatitis C – Annual epidemiological report 2024. Stockholm: ECDC; 2024 [cited 2026 Jan 15]. Available from: https://www.ecdc.europa.eu/en/publications-data/prevention-hepatitis-b-and-c-eueea-2024

Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injecting drug use to hepatitis C virus transmission globally. Lancet Gastroenterol Hepatol. 2019;4(6):435–444. DOI: https://doi.org/10.1016/S2468-1253(19)30097-3

Ha S, Timmerman K. Awareness and knowledge of hepatitis C among health care providers and the public: a scoping review. Can Commun Dis Rep. 2018;44(7-8):157–165. DOI: https://doi.org/10.14745/ccdr.v44i78a02

Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection. Lancet Gastroenterol Hepatol. 2017;2(3):161–176. DOI: https://doi.org/10.1016/S2468-1253(16)30181-9

Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int. 2011;31(Suppl 2):1–3. DOI: https://doi.org/10.1111/j.1478-3231.2011.02537.x

World Health Organization. Global health sector strategy on viral hepatitis 2022-2030. Geneva: WHO; 2022 [cited 2026 Jan 15]. Available from: https://www.who.int/publications/i/item/9789240053779

European Centre for Disease Prevention and Control. Hepatitis B and C testing activities, needs, and priorities in the EU/EEA. Stockholm: ECDC; 2021 [cited 2026 Jan 15]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/HepatitisBC-testing-in-EU-May2017.pdf

Grebely J, Dore GJ. Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis. 2011;203(5):571–574. DOI: https://doi.org/10.1093/infdis/jiq111

Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C. J Hepatol. 2018;68(4):857–859. DOI: https://doi.org/10.1016/j.jhep.2017.12.033

European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. J Hepatol. 2020;73(5):1170–1218. DOI: https://doi.org/10.1016/j.jhep.2020.08.018

Downloads

Published

2026-07-14

How to Cite

Яньова, З., Беловічова, М., & Червена, Л. (2026). Spatiotemporal Trends of Hepatitis C in Slovakia: A Joinpoint and GIS-Based Analysis (2015–2025). Ukraine. Nation’s Health, (2), 43–49. https://doi.org/10.32782/2077-6594/2026.2/05

Issue

Section

Public health